03:26 PM EST - Tetra Bio-Pharma Inc. : Today announced positive initial clinical data from its ongoing Phase 2 clinical trials of QIXLEEF™for cancer pain. QIXLEEF™ is a botanical inhaled investigational new drug with a fixed ratio of THC and CBD that meets USA cGMP regulatory requirements. Tetra Bio-Pharma Inc.
shares T.TBP are trading up 0.03 cents at $0.23.
